Yangli Pharmaceutical Raises 100 Million Yuan Series B to Advance Anti-Tumor and Chronic Disease Pipeline
核心洞察
Yangli Pharmaceutical completed a 100 million yuan Series B financing round exclusively led by Qiming Venture Partners to advance multiple clinical-stage products.
The company's pipeline includes the highly selective aldosterone synthase inhibitor VB19055 (搜索) and small-molecule targeted drugs TFX05 (搜索), TFX06, and VB15 for hypertension and solid tumors.
Founded in 2021, the Hangzhou-based company focuses on first-in-class and best-in-class innovative drugs with global intellectual property rights.
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. has secured 100 million yuan in Series B financing exclusively from Qiming Venture Partners, marking a significant milestone for the three-year-old innovative drug developer as it advances multiple clinical-stage programs targeting cancer and chronic diseases.
The Hangzhou-based company, founded in 2021, will use the funding to accelerate clinical development of its differentiated pipeline, which includes products already in Phase I and Phase II trials. Existing shareholders include Taifu Capital, Hangzhou State-owned Assets, and Runzhang Venture Capital.
Clinical Pipeline Shows Promise Across Multiple Indications
Yangli Pharmaceutical's current clinical portfolio features the highly selective aldosterone synthase inhibitor VB19055 (搜索) for hypertension, alongside small-molecule targeted drugs TFX05 (搜索), TFX06, and VB15 for various solid tumors. The company's pre-clinical pipeline extends to small-molecule and small-nucleic-acid therapies covering tumors, hypertension, hyperlipidemia, and diabetes.
The company follows an "In China, For Global" R&D strategy, developing Class 1 innovative drugs with global intellectual property rights that are designed to be first-in-class or best-in-class therapeutics addressing unmet clinical needs.
Experienced Leadership Team Drives Innovation
The company's leadership brings extensive pharmaceutical industry experience. Dr. Sha Wei, founder and president, previously served as general manager of Taifeng Research Institute of Taifeng Pharmaceutical Group and brings comprehensive experience spanning drug R&D through product launch.
Co-founder and chairman Dr. Ding Zhaozhong contributes over 30 years of drug R&D and management experience. Chief Scientific Officer Dr. Fang Dong has more than 20 years in drug discovery and development, having participated in the R&D of several marketed anti-tumor drugs including Lisaftoclax, Olverembatinib, Iruplinalkib, and Glasdegib. Dr. Fang has promoted dozens of new drug clinical trial applications in China and the United States, published over 40 peer-reviewed papers, and holds more than 20 patents.
Recognition and Future Outlook
Yangli Pharmaceutical has earned recognition as a national high-tech enterprise, a national technology-based small and medium-sized enterprise, and an innovative small and medium-sized enterprise in Zhejiang Province. The company was also designated as a talent-leading demonstration enterprise in 2024 and selected for the ninth batch of "Dayun Talents" innovation and entrepreneurship projects.
"The successful completion of this round of financing fully demonstrates the investors' high recognition of the clinical competitiveness and market potential of our pipelines," said Dr. Ding Zhaozhong. "This financing paves the way for our anti-tumor product line to enter registration-based clinical trials and for our chronic disease products to obtain clinical validation."
Dr. Chen Kan, partner at Qiming Venture Partners and co-head of the medical innovation industry, highlighted the company's differentiated approach: "Yangli Pharmaceutical creates differentiated innovation from the source with its forward-looking target project establishment and efficient compound optimization platform, and has developed a series of candidate molecules with high activity, high specificity, and excellent safety."
The financing positions Yangli Pharmaceutical to transition from clinical validation to rapid commercialization, bringing the company closer to delivering innovative therapies to address urgent clinical needs for global patients.